tradingkey.logo

Kyverna Therapeutics Inc <KYTX.OQ> expected to post a loss of $1.11 a share - Earnings Preview

ReutersMay 9, 2025 9:47 PM
  • Kyverna Therapeutics Inc KYTX.OQ KYTX.O is expected to show no change in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Kyverna Therapeutics Inc is for a loss of $1.11 per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had fallen by about 4.1% in the last three months. ​

  • Wall Street's median 12-month price target for Kyverna Therapeutics Inc is $20.00​, above​ its last closing price of $2.13. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.84

-0.88

Missed

-5

Sep. 30 2024

-0.79

-0.79

-0.80

Missed

-1.5

Jun. 30 2024

-0.69

-0.70

-0.67

Beat

4​

Mar. 31 2024

-0.96

-0.84

-1.12

Missed

-33.3

​​Dec. 31 2023

-3.23

-3.23

-26.86

Missed

-732.4

This summary was machine generated May 9 at 21:47 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI